{"id":"W4292411599","doi":"10.1016/j.esmoop.2022.100562","title":"Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; PharmaMar; Servier; Astellas Pharma; Eisai; Incyte; Seagen; Gilead Sciences; Ipsen; BeiGene; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Oncology; Adverse effect; Tolerability; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003825031,0.0003092305,0.0007382605,0.0001711625,0.0004579587,0.0001596943,0.00106901,0.00003390767,0.0009553253],"category_scores_gemma":[0.0002179458,0.0002425758,0.00002931245,0.0004252139,0.00005048436,0.0005273239,0.003257085,0.0004790561,0.00007372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007139581,"about_ca_system_score_gemma":0.000394824,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01771855,"about_ca_topic_score_gemma":0.002371268,"domain_scores_codex":[0.9967564,0.000306983,0.0005674392,0.0008980584,0.0008562973,0.0006148246],"domain_scores_gemma":[0.9983233,0.0001058384,0.0001960355,0.0009360426,0.000124347,0.0003144237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4293551,0.1491953,0.3347297,0.00002704464,0.001202169,0.005460724,0.01286879,0.0001213231,0.00008097537,0.000006200405,0.003895324,0.06305736],"study_design_scores_gemma":[0.574192,0.02830125,0.3898916,0.0001777178,0.00008293458,0.000003788053,0.002162465,0.001129794,0.0001980728,0.00001250345,0.003517066,0.0003308601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858233,0.000024782,0.000001643855,0.0004158494,0.00008967653,0.009768686,0.001094603,0.00003215649,0.002749339],"genre_scores_gemma":[0.9928691,0.000003895088,0.001199512,0.000301548,0.00002578166,0.001466357,0.00226761,0.00005945077,0.001806793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1448369,"threshold_uncertainty_score":0.9999579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0494886679412191,"score_gpt":0.3824033392055332,"score_spread":0.3329146712643141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}